Page 1283 - Williams Hematology ( PDFDrive )

1258 Part IX: Lymphocytes and Plasma Cells Chapter 81: Hematologic Manifestations of Acquired Immunodeficiency Syndrome 1259

Physicians in Private Practice Treating HIV-Infected Patients (DAGNA), in coopera- 230. Ray A, Marshall V, Uldrick T, et al: Sequence analysis of Kaposi sarcoma-associated
tion with the German AIDS Society (DAIG). Ann Hematol 93:913–921, 2014. herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease
201. Rudek MA, Flexner C, Ambinder RF: Use of antineoplastic agents in patients with and KSHV-associated inflammatory cytokine syndrome. J Infect Dis 205:1665–1676,
cancer who have HIV/AIDS. Lancet Oncol 12:905–912, 2011. 2012.
202. Torres HA, Rallapalli V, Saxena A, et al: Efficacy and safety of antiretrovirals in HIV- 231. Uldrick TS, Wang V, O’Mahony D, et al: An interleukin-6-related systemic inflamma-
infected patients with cancer. Clin Microbiol Infect 20:O672–O679, 2014. tory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and
203. Bower M, McCall-Peat N, Ryan N, et al: Protease inhibitors potentiate chemotherapy- HIV but without Multicentric Castleman disease. Clin Infect Dis 51:350–358, 2010.
induced neutropenia. Blood 104:2943–2946, 2004. 232. Niedt GW, Schinella RA: Acquired immunodeficiency syndrome. Clinicopathologic
204. Bower M, Powles T, Stebbing J, et al: Potential antiretroviral drug interactions with study of 56 autopsies. Arch Pathol Lab Med 109:727–734, 1985.
cyclophosphamide, doxorubicin, and etoposide. J Clin Oncol 23:1328–1329; author 233. Jordan MB, Allen CE, Weitzman S, et al: How I treat hemophagocytic lymphohistiocy-
reply 1329–1330, 2005. tosis. Blood 118:4041–4052, 2011.
205. Sparano JA, Lee S, Chen MG, et al: Phase II trial of infusional cyclophosphamide, dox- 234. Fardet L, Lambotte O, Meynard JL, et al: Reactive haemophagocytic syndrome in 58
orubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma: HIV-1-infected patients: Clinical features, underlying diseases and prognosis. AIDS
An Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 22:1491–1500, 24:1299–1306, 2010.
2004. 235. Trottestam H, Horne A, Arico M, et al: Chemoimmunotherapy for hemophagocytic
206. Wong AY, Marcotte S, Laroche M, et al: Safety and efficacy of CHOP for treatment of lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood
diffuse large B-cell lymphoma with different combination antiretroviral therapy regi- 118:4577–4584, 2011.
mens: SCULPT study. Antivir Ther 18:699–707, 2013. 236. Henter JI, Horne A, Arico M, et al: HLH-2004: Diagnostic and therapeutic guidelines
207. Ezzat HM, Cheung MC, Hicks LK, et al: Incidence, predictors and significance of for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131, 2007.
severe toxicity in patients with human immunodeficiency virus-associated Hodgkin 237. Sullivan PS, Hanson DL, Chu SY, et al: Epidemiology of anemia in human immunode-
lymphoma. Leuk Lymphoma 53:2390–2396, 2012. ficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent
208. Oksenhendler E, Boulanger E, Galicier L, et al: High incidence of Kaposi sarcoma- spectrum of HIV disease surveillance project. Blood 91:301–308, 1998.
associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection 238. Mocroft A, Kirk O, Barton SE, et al: Anaemia is an independent predictive marker for
and multicentric Castleman disease. Blood 99:2331–2336, 2002. clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group.
209. Powles T, Stebbing J, Bazeos A, et al: The role of immune suppression and HHV-8 in the AIDS 13:943–950, 1999.
increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol 239. Mocroft A, Lifson AR, Touloumi G, et al: Haemoglobin and anaemia in the SMART
20:775–779, 2009. study. Antivir Ther 16:329–337, 2011.
210. Carbone A, De Paoli P, Gloghini A, et al: KSHV-associated multicentric Castleman 240. Berhane K, Karim R, Cohen MH, et al: Impact of highly active antiretroviral therapy on
disease: A tangle of different entities requiring multitarget treatment strategies. Int J anemia and relationship between anemia and survival in a large cohort of HIV-infected
Cancer 137:251–261, 2015. women: Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 37:1245–1252,
211. Polizzotto MN, Uldrick TS, Wang V, et al: Human and viral interleukin-6 and other 2004.
cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. 241. Hoffmann CJ, Fielding KL, Johnston V, et al: Changing predictors of mortality over
Blood 122:4189–4198, 2013. time from cART start: Implications for care. J Acquir Immune Defic Syndr 58:269–276,
212. Qu L, Jenkins F, Triulzi DJ: Human herpesvirus 8 genomes and seroprevalence in 2011.
United States blood donors. Transfusion 50:1050–1056, 2010. 242. Mocroft A, Ledergerber B, Zilmer K, et al: Short-term clinical disease progression in
213. Hoffmann C, Schmid H, Muller M, et al: Improved outcome with rituximab in patients HIV-1-positive patients taking combination antiretroviral therapy: The EuroSIDA risk-
with HIV-associated multicentric Castleman disease. Blood 118:3499–3503, 2011. score. AIDS 21:1867–1875, 2007.
214. Gerard L, Michot JM, Burcheri S, et al: Rituximab decreases the risk of lymphoma in 243. Tate JP, Justice AC, Hughes MD, et al: An internationally generalizable risk index for
patients with HIV-associated multicentric Castleman disease. Blood 119:2228–2233, mortality after one year of antiretroviral therapy. AIDS 27:563–572, 2013.
2012. 244. Justice AC, Modur SP, Tate JP, et al: Predictive accuracy of the Veterans Aging Cohort
215. Oksenhendler E, Carcelain G, Aoki Y, et al: High levels of human herpesvirus 8 viral Study index for mortality with HIV infection: A North American cross cohort analysis.
load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacer- J Acquir Immune Defic Syndr 62:149–163, 2013.
bation of multicentric Castleman disease in HIV-infected patients. Blood 96:2069–2073, 245. Moses AV, Williams S, Heneveld ML, et al: Human immunodeficiency virus infection
2000. of bone marrow endothelium reduces induction of stromal hematopoietic growth fac-
216. Stebbing J, Adams C, Sanitt A, et al: Plasma HHV8 DNA predicts relapse in individuals tors. Blood 87:919–925, 1996.
with HIV-associated multicentric Castleman disease. Blood 118:271–275, 2011. 246. Drakesmith H, Prentice AM: Hepcidin and the iron-infection axis. Science 338:
217. Bower M: How I treat HIV-associated multicentric Castleman disease. Blood 116: 768–772, 2012.
4415–4421, 2010. 247. Wisaksana R, de Mast Q, Alisjahbana B, et al: Inverse relationship of serum hepcidin
218. Bower M, Powles T, Williams S, et al: Brief communication: Rituximab in HIV-associated levels with CD4 cell counts in HIV-infected patients selected from an Indonesian pro-
multicentric Castleman disease. Ann Intern Med 147:836–839, 2007. spective cohort study. PLoS One 8:e79904, 2013.
219. Gerard L, Berezne A, Galicier L, et al: Prospective study of rituximab in chemother- 248. Redd AD, Avalos A, Essex M: Infection of hematopoietic progenitor cells by HIV-1
apy-dependent human immunodeficiency virus associated multicentric Castleman’s subtype C, and its association with anemia in southern Africa. Blood 110:3143–3149,
disease: ANRS 117 CastlemaB Trial. J Clin Oncol 25:3350–3356, 2007. 2007.
220. Bower M, Veraitch O, Szydlo R, et al: Cytokine changes during rituximab therapy in 249. Carter CC, Onafuwa-Nuga A, McNamara LA, et al: HIV-1 infects multipotent pro-
HIV-associated multicentric Castleman disease. Blood 113:4521–4524, 2009. genitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16:
221. Powles T, Stebbing J, Montoto S, et al: Rituximab as retreatment for rituximab pre- 446–451, 2010.
treated HIV-associated multicentric Castleman disease. Blood 110:4132–4133, 2007. 250. McNamara LA, Onafuwa-Nuga A, Sebastian NT, et al: CD133+ hematopoietic progen-
222. Marcelin AG, Aaron L, Mateus C, et al: Rituximab therapy for HIV-associated Castle- itor cells harbor HIV genomes in a subset of optimally treated people with long-term
man disease. Blood 102:2786–2788, 2003. viral suppression. J Infect Dis 207:1807–1816, 2013.
223. Uldrick TS, Polizzotto MN, Aleman K, et al: Rituximab plus liposomal doxorubicin 251. Nixon CC, Vatakis DN, Reichelderfer SN, et al: HIV-1 infection of hematopoietic pro-
in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood genitor cells in vivo in humanized mice. Blood 122:2195–2204, 2013.
124:3544–3552, 2014. 252. Camacho J, Poveda F, Zamorano AF, et al: Serum erythropoietin levels in anaemic
224. van Rhee F, Wong RS, Munshi N, et al: Siltuximab for multicentric Castleman’s disease: patients with advanced human immunodeficiency virus infection. Br J Haematol
A randomised, double-blind, placebo-controlled trial. Lancet Oncol 15:966–974, 2014. 82:608–614, 1992.
225. Kurzrock R, Voorhees PM, Casper C, et al: A phase I, open-label study of siltuximab, 253. Spivak JL, Barnes DC, Fuchs E, et al: Serum immunoreactive erythropoietin in HIV-
an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, infected patients. JAMA 261:3104–3107, 1989.
multiple myeloma, or Castleman disease. Clin Cancer Res 19:3659–3670, 2013. 254. Tsiakalos A, Kordossis T, Ziakas PD, et al: Circulating antibodies to endogenous ery-
226. Nagao A, Nakazawa S, Hanabusa H: Short-term efficacy of the IL6 receptor antibody thropoietin and risk for HIV-1-related anemia. J Infect 60:238–243, 2010.
tocilizumab in patients with HIV-associated multicentric Castleman disease: Report of 255. Tsiakalos A, Routsias JG, Kordossis T, et al: Fine epitope specificity of anti-erythropoietin
two cases. J Hematol Oncol 7:10, 2014. antibodies reveals molecular mimicry with HIV-1 p17 protein: A pathogenetic mecha-
227. Casper C, Nichols WG, Huang ML, et al: Remission of HHV-8 and HIV-associated nism for HIV-1-related anemia. J Infect Dis 204:902–911, 2011.
multicentric Castleman disease with ganciclovir treatment. Blood 103:1632–1634, 256. Behler C, Shade S, Gregory K, et al: Anemia and HIV in the antiretroviral era: Potential
2004. significance of testosterone. AIDS Res Hum Retroviruses 21:200–206, 2005.
228. Uldrick TS, Polizzotto MN, Aleman K, et al: High-dose zidovudine plus valganciclo- 257. Young NS, Brown KE: Parvovirus B19. N Engl J Med 350:586–597, 2004.
vir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: A pilot 258. Koduri PR: Parvovirus B19-related anemia in HIV-infected patients. AIDS Patient Care
study of virus-activated cytotoxic therapy. Blood 117:6977–6986, 2011. STDS 14:7–11, 2000.
229. Polizzotto MN, Uldrick TS, Hu D, et al: Clinical manifestations of Kaposi sarcoma her- 259. Abkowitz JL, Brown KE, Wood RW, et al: Clinical relevance of parvovirus B19 as a
pesvirus lytic activation: Multicentric Castleman disease (KSHV-MCD) and the KSHV cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis
inflammatory cytokine syndrome. Front Microbiol 3:73, 2012. 176:269–273, 1997.

Kaushansky_chapter 81_p1239-1260.indd 1258 9/21/15 11:19 AM